Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe8ψ(CH2NH)Arg9]-BK in a F98 glioma rat model: An MRI study

Neuropeptides

Volumn 44, Issue 2, 2010, Pages 177-185

  Côté, Jérôme ^a   Savard, Martin ^a   Bovenzi, Veronica ^a   Dubuc, Céléna ^a   Tremblay, Luc ^a   Tsanaclis, Ana Maria ^a   Fortin, David ^a   Lepage, Martin ^a   Gobeil Jr , Fernand ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Brain cancer; G protein coupled receptor; Kinins; MRI; Rat; Vascular permeability

Indexed keywords

BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR AGONIST; GADOLINIUM PENTETATE; GADOMER 17; ICATIBANT; MECLOFENAMIC ACID; NITRIC OXIDE SYNTHASE INHIBITOR; NITRIC OXIDE SYNTHASE INHIBITOR L NA; R 523; R 892; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SELECTIVITY; DRUG TARGETING; DRUG UPTAKE; FISCHER 344 RAT; GLIOMA; HYDROPHILICITY; HYPOTENSION; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE STUDY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION;

ANIMALS; BLOOD PRESSURE; BLOOD-BRAIN BARRIER; BRADYKININ; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; GLIOMA; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM TRANSPLANTATION; NITRIC OXIDE; RATS; RATS, INBRED F344; RECEPTOR, BRADYKININ B2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

RATTUS;

EID: 77049084023     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2009.12.009     Document Type: Article

References (44)

1. Adamson C., Kanu O.O., Mehta A.I., Di C., Lin N., Mattox A.K., and Bigner D.D. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin. Investig. Drugs 18 (2009) 1061-1083
2. Arganaraz G.A., Silva Jr. J.A., Perosa S.R., Pessoa L.G., Carvalho F.F., Bascands J.L., Bader M., da Silva Trindade E., Amado D., Cavalheiro E.A., Pesquero J.B., and da Graca Naffah-Mazzacoratti M. The synthesis and distribution of the kinin B1 and B2 receptors are modified in the hippocampus of rats submitted to pilocarpine model of epilepsy. Brain Res. 1006 (2004) 114-125
3. Asotra K., Ningaraj N., and Black K.L. Measurement of blood-brain and blood-tumor barrier permeabilities with [14C]-labeled tracers. Methods Mol. Med. 89 (2003) 177-190
4. Barnhart J.L., Kuhnert N., Bakan D.A., and Berk R.N. Biodistribution of GdCl3 and Gd-DTPA and their influence on proton magnetic relaxation in rat tissues. Magn. Reson. Imaging 5 (1987) 221-231
5. Barth R.F. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neurooncol. 36 (1998) 91-102
6. Barth R.F., and Kaur B. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J. Neurooncol. 94 (2009) 299-312
7. Bartus R.T., Elliott P.J., Dean R.L., Hayward N.J., Nagle T.L., Huff M.R., Snodgrass P.A., and Blunt D.G. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp. Neurol. 142 (1996) 14-28
8. Bélanger S., Bovenzi V., Côté J., Neugebauer W., Amblard M., Martinez J., Lammek B., Savard M., and Gobeil Jr. F. Structure-activity relationships of novel peptide agonists of the human bradykinin B2 receptor. Peptides 30 (2009) 777-787
9. Black K.L. Biochemical opening of the blood-brain barrier. Adv. Drug Deliv. Rev. 15 (1995) 37
10. Blanchette M., Pellerin M., Tremblay L., Lepage M., and Fortin D. Real-time monitoring of gadolinium diethylenetriamine penta-acetic acid during osmotic blood-brain barrier disruption using magnetic resonance imaging in normal wistar rats. Neurosurgery 65 (2009) 344-350
11. Brown J.J., Hynes M.R., and Wible Jr. J.H. Measurement of serum calcium concentration after administration of four gadolinium-based contrast agents to human volunteers. AJR Am. J. Roentgenol. 189 (2007) 1539-1544
12. Bryant M.J., Chuah T.L., Luff J., Lavin M.F., and Walker D.G. A novel rat model for glioblastoma multiforme using a bioluminescent F98 cell line. J. Clin. Neurosci. 15 (2008) 545-551
13. Chen E.Y., Emerich D.F., Bartus R.T., and Kordower J.H. B2 bradykinin receptor immunoreactivity in rat brain. J. Comp. Neurol. 427 (2000) 1-18
14. Côté, J., Tremblay, L., Fortin, D., Gobeil, F., Jr., Lepage, M., 2007. Assessment of bradykinin B2 receptor mediated-selective blood brain barrier opening in a F98 glioma rat model by non invasive magnetic resonance imaging. In: Proceedings of Society of Magnetic Resonance in Medicine, vol. 15, 2835p..
15. 9]bradykinin, a B2 receptor selective agonist which is not broken down by either kininase I or kininase II. Eur. J. Pharmacol. 155 (1988) 193-195
16. Elliott P.J., Hayward N.J., Huff M.R., Nagle T.L., Black K.L., and Bartus R.T. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp. Neurol. 141 (1996) 214-224
17. Emerich D.F., Dean R.L., Osborn C., and Bartus R.T. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation. Clin. Pharmacokinet. 40 (2001) 105-123
18. Ferrier M.C., Sarin H., Fung S.H., Schatlo B., Pluta R.M., Gupta S.N., Choyke P.L., Oldfield E.H., Thomasson D., and Butman J.A. Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia 9 (2007) 546-555
19. Fortier A., Bovenzi V., Fortin D., and Gobeil Jr. F. Étude de l'expression des récepteurs B1 et B2 des kinines chez les glioblastomes multiformes humains. Med. Sci. 22 suppl. 2 (2006) 24
20. Fortin D. The blood-brain barrier should not be underestimated in neuro-oncology. Rev. Neurol. 160 (2004) 523-532
21. Gobeil Jr. F., Charland S., Filteau C., Perron S.I., Neugebauer W., and Regoli D. Kinin B1 receptor antagonists containing alpha-methyl-l-phenylalanine: in vitro and in vivo antagonistic activities. Hypertension 33 (1999) 823-829
22. Gobeil Jr. F., Zhu T., Brault S., Geha A., Vazquez-Tello A., Fortier A., Barbaz D., Checchin D., Hou X., Nader M., Bkaily G., Gratton J.P., Heveker N., Ribeiro-da-Silva A., Peri K., Bard H., Chorvatova A., D'Orleans-Juste P., Goetzl E.J., and Chemtob S. Nitric oxide signaling via nuclearized endothelial nitric-oxide synthase modulates expression of the immediate early genes iNOS and mPGES-1. J. Biol. Chem. 281 (2006) 16058-16067
23. Kemper E.M., Boogerd W., Thuis I., Beijnen J.H., and van Tellingen O. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?. Cancer Treat. Rev. 30 (2004) 415-423
24. Liu Y., Hashizume K., Chen Z., Samoto K., Ningaraj N., Asotra K., and Black K.L. Correlation between bradykinin-induced blood-tumor barrier permeability and B2 receptor expression in experimental brain tumors. Neurol. Res. 23 (2001) 379-387
25. Liu L.B., Xue Y.X., Liu Y.H., and Wang Y.B. Bradykinin increases blood-tumor barrier permeability by down-regulating the expression levels of ZO-1, occludin, and claudin-5 and rearranging actin cytoskeleton. J. Neurosci. Res. 86 (2008) 1153-1168
26. Mathieu D., Lecomte R., Tsanaclis A.M., Larouche A., and Fortin D. Standardization and detailed characterization of the syngeneic Fischer/F98 glioma model. Can. J. Neurol. Sci. 34 (2007) 296-306
27. Misselwitz B., Schmitt-Willich H., Ebert W., Frenzel T., and Weinmann H.J. Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent. Magma 12 (2001) 128-134
28. Neuwelt E.A. Mechanisms of disease: the blood-brain barrier. Neurosurgery 54 (2004) 131-140
29. Prados M.D., Schold S.J.S., Fine H.A., Jaeckle K., Hochberg F., Mechtler L., Fetell M.R., Phuphanich S., Feun L., Janus T.J., Ford K., and Graney W. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neurooncol. 5 (2003) 96-103
30. Raidoo D.M., Sawant S., Mahabeer R., and Bhoola K.D. Kinin receptors are expressed in human astrocytic tumour cells. Immunopharmacology 43 (1999) 255-263
31. Rapoport S.I. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell. Mol. Neurobiol. 20 (2000) 217-230
32. Riley M.G., Kim N.N., Watson V.E., Gobin Y.P., LeBel C.P., Black K.L., and Bartus R.T. Intra-arterial administration of carboplatin and the blood brain barrier permeabilizing agent, RMP-7: a toxicologic evaluation in swine. J. Neurooncol. 36 (1998) 167-178
33. Sarin H., Kanevsky A.S., Fung S.H., Butman J.A., Cox R.W., Glen D., Reynolds R., and Auh S. Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J. Transl. Med. 7 (2009) 33
34. Savard M., Barbaz D., Bélanger S., Muller-Esterl W., Bkaily G., D'Orléans-Juste P., Côté J., Bovenzi V., and Gobeil Jr. F. Expression of endogenous nuclear bradykinin B2 receptors mediating signaling in immediate early gene activation. J. Cell. Physiol. 216 (2008) 234-244
35. Schor N.F. Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol. Ther. 121 (2009) 253-264
36. Sugita M., and Black K.L. Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors. Cancer Res. 58 (1998) 914-920
37. Venema R.C. Post-translational mechanisms of endothelial nitric oxide synthase regulation by bradykinin. Int. Immunopharmacol. 2 (2002) 1755-1762
38. Verhoye M., van der Sanden B.P., Rijken P.F., Peters H.P., Van der Kogel A.J., Pee G., Vanhoutte G., Heerschap A., and Van der Linden A. Assessment of the neovascular permeability in glioma xenografts by dynamic T(1) MRI with Gadomer-17. Magn. Reson. Med. 47 (2002) 305-313
39. Wahl M., Gorlach C., Hortobagyi T., and Benyo Z. Effects of bradykinin in the cerebral circulation. Acta Physiol. Hung. 86 (1999) 155-160
40. Warren K., Jakacki R., Widemann B., Aikin A., Libucha M., Packer R., Vezina G., Reaman G., Shaw D., Krailo M., Osborne C., Cehelsky J., Caldwell D., Stanwood J., Steinberg S.M., and Balis F.M. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother. Pharmacol. 58 (2006) 343-347
41. Wirth K., Hock F.J., Albus U., Linz W., Alpermann H.G., Anagnostopoulos H., Henk S., Breipohl G., Konig W., Knolle J., et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol. 102 (1991) 774-777
42. Wu J., Akaike T., and Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58 (1998) 159-165
43. Yin D., Wang X., Konda B.M., Ong J.M., Hu J., Sacapano M.R., Ko M.K., Espinoza A.J., Irvin D.K., Shu Y., and Black K.L. Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors. Clin. Cancer Res. 14 (2008) 4002-4009
44. Zhao Y., Xue Y., Liu Y., Fu W., Jiang N., An P., Wang P., Yang Z., and Wang Y. Study of correlation between expression of bradykinin B2 receptor and pathological grade in human gliomas. Br. J. Neurosurg. 19 (2005) 322-326